Received May 7, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | — | — |
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | — | — |
Suspected vaccination failure; I contracted Shingles; This serious case was reported by a consumer via call center representative and described the occurrence of vaccination failure in a patient who received Herpes zoster (Shingrix) for prophylaxis. Co-suspect products included Herpes zoster (Shingrix) for prophylaxis. On 25-SEP-2020, the patient received the 1st dose of Shingrix. On 20-MAR-2021, the patient received the 2nd dose of Shingrix. On 21-MAR-2026, 2003 days after receiving Shingrix and 1827 days after receiving Shingrix, the patient experienced vaccination failure (Verbatim: Suspected vaccination failure) (serious criteria GSK medically significant) and shingles (Verbatim: I contracted Shingles). The outcome of the vaccination failure and shingles were not reported. It was unknown if the reporter considered the vaccination failure and shingles to be related to Shingrix and Shingrix. It was unknown if the company considered the vaccination failure and shingles to be related to Shingrix and Shingrix. Additional Information: GSK Receipt Date:15-APR-2026 The individual had received the first dose of the Shingrix vaccine. The individual had received the second dose. The individual developed shingles. The individual reported being surprised to have developed the condition exactly five years after the second dose. This case was considered as suspected vaccination failure as details regarding completion of laboratory test confirming shingles were unknown at the time of reporting. The batch number was not provided and a request for this information has been made.; Sender's Comments: A case of Vaccination failure, 1827 days after receiving 1st dose and 2nd dose of Shingrix in a patient. Case lacks further information on medical history, concurrent conditions and laboratory confirmation. Based on the available information a possible causality that the event was caused by the GSK product cannot be ascertained. Consent for further follow-up has not been received.